210 related articles for article (PubMed ID: 21713004)
1. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.
van Hal SJ; Jones M; Gosbell IB; Paterson DL
PLoS One; 2011; 6(6):e21217. PubMed ID: 21713004
[TBL] [Abstract][Full Text] [Related]
2. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
3. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.
Sancak B; Yagci S; Gür D; Gülay Z; Ogunc D; Söyletir G; Yalcin AN; Dündar DO; Topçu AW; Aksit F; Usluer G; Ozakin C; Akalin H; Hayran M; Korten V
BMC Infect Dis; 2013 Dec; 13():583. PubMed ID: 24325260
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
[TBL] [Abstract][Full Text] [Related]
6. Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?
Claeys KC; Lagnf AM; Hallesy JA; Compton MT; Gravelin AL; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2016 Jan; 60(3):1708-16. PubMed ID: 26729497
[TBL] [Abstract][Full Text] [Related]
7. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
8. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and molecular characteristics of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern China.
Cheng X; Ma L; Wang Y; Sun W; Su J
Diagn Microbiol Infect Dis; 2024 Mar; 108(3):116180. PubMed ID: 38183897
[TBL] [Abstract][Full Text] [Related]
10. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
Casapao AM; Davis SL; McRoberts JP; Lagnf AM; Patel S; Kullar R; Levine DP; Rybak MJ
Antimicrob Agents Chemother; 2014 Aug; 58(8):4636-41. PubMed ID: 24890596
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.
Park KH; Kim ES; Kim HS; Park SJ; Bang KM; Park HJ; Park SY; Moon SM; Chong YP; Kim SH; Lee SO; Choi SH; Jeong JY; Kim MN; Woo JH; Kim YS
J Antimicrob Chemother; 2012 Aug; 67(8):1843-9. PubMed ID: 22535621
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.
Musta AC; Riederer K; Shemes S; Chase P; Jose J; Johnson LB; Khatib R
J Clin Microbiol; 2009 Jun; 47(6):1640-4. PubMed ID: 19369444
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
[TBL] [Abstract][Full Text] [Related]
16. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.
van Hal SJ; Wehrhahn MC; Barbagiannakos T; Mercer J; Chen D; Paterson DL; Gosbell IB
J Clin Microbiol; 2011 Apr; 49(4):1489-94. PubMed ID: 21270232
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
Ozmen Capin BB; Tekeli A; Karahan ZC
Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
[No Abstract] [Full Text] [Related]
18. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.
Takata T; Miyazaki M; Futo M; Hara S; Shiotsuka S; Kamimura H; Yoshimura H; Matsunaga A; Nishida T; Ishikura H; Ishikawa T; Tamura K; Tsuji BT
Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR
PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
